Monoclonal antibodies and methods for fungal pathogen detection

Abstract

This invention provides monoclonal antibodies useful for the detection of Phythiaceae infection of plants. Hybridoma producing the antibodies as well as materials and kits for carrying out the detection of the organisms are also disclosed.

Description

FIELD OF THE INVENTION

This invention relates to the field of diagnostic plant pathology. More specifically the invention relates to the immunological detection of various taxa of fungi known to be the etiologic agents of a variety of plant diseases.

BACKGROUND OF THE INVENTION

Fungi as a group cause many plant diseases. For purposes of discussion the fungi can be classified as belonging to one of three major taxonomic classes: Ascomycetes, Basidiomyctes, or Phycomycetes.

Ascomycetes

Members of this class possess a specialized reproductive structure (an ascus) in which meiosis and sexual spore formation take place. Examples of the more common plant diseases in which Ascomycetes have been identified as the etiologic agent include: powdery mildews on cereals, fruits and many other crops; Dutch elm disease; ergot of grains; peach and plum brown rot; black spot of roses as well as apple scab.

Basidiomycetes

Members of this class are identified by the presence of a sexual-spore forming structure known as a basidium. Pathogenic forms include smuts, rusts and fleshy species such as mushrooms. Examples include wheat rust, white pine blister, cedar-apple rust, and smuts causing disease in corn, oats, barley, onions and wheat.

Phycomycetes

Members of this class are considered to be more primitive than members of either the Ascomycetes or Basidiomycetes, their distinguishing morphological feature being the absence of mycelial crosswalls. Examples of disease caused by members of the class include the downy mildews of grape and other hosts, root rot and late blight of potato and tomato.

In the context of this invention, members of the genus Pythium are particularly important. Description of the genus date to the mid-1800's and several excellent monographs exist that provide detailed taxonomic and morphological description of the various species within the genus (See for example Waterhouse G. M., Mycological Papers, No. 110 (1968); and Middleton, J. T., Mem. Torrey bot. Club 20 (1): 1-171 (1943)). Pythium belongs to the family Pythiaceae which includes 7 genera and about 180 species. Pythium represents the most important genus comprising over 100 species. Some of the more important species are summarized in Table 1.

TABLE I______________________________________Various Diseases in which Pythium spp.have been Identified As Etiologic AgentsSpecies Disease______________________________________P. acanthicum Blossom end rot of Citrullus vulgarisP. aphanidermatum Bean, strawberry seedling dampening off, root rot, turf blightP. aroiosporon Root disease of wheatP. arrhenomanes Root decay of maizeP. arrhenomanes Root rot of tomato, wheat, barley,Var. canadense rice and maizeP. artotrogus Root disease of Anas satiuusP. butleri Parasite of Nicotiana tabacumP. colorantumP. dissotocum Rootlet of Saccharun officinerumP. fabae Root rot of Vicia fabaP. helicoides Root decay of Phaseolus vulgarisP. horinouchiense Snow-blight of wheatP. mamillatum root rot of sugar beetP. myriotylum fruit decay of Cucumis sativusP. paroecandrum root discloration of Allium vincaleP. salpigophorum root decay of Pisum sativumP. salpingopserumP. sylvaticumP. ultimumP. volutum root rot of wheat, barley secale and Zea mays______________________________________

In an attempt to resolve certain taxonomic discrepancies polyclonal antisera to several Pythium species were generated by Krywiesncyzk and Dorworth (Can. J. Botany 58: 1412 (1980)) and cross-reactivity was measured. The nine species studied could be placed into four groups based on their immunological cross reactivity or lack thereof when tested against each other by double diffusion and immunoelectrophoretic techniques.

HYBRIDOMA MONOCLONAL ANTIBODY TECHNOLOGY

The use of somatic hybrid cell lines as sources of antibody to individual antigens generally dates from the work of Kohler and Milstein (Nature 256: 495-97 (1975)). The antibodies produced are quite different than those recovered from antiserum from conventionally immunized animals. Each hybrid cell line synthesizes a homogenous immunoglobulin that represents but one of the myriad of types of antibodies that an animal can synthesize in response to an antigen in vivo. Since each immunoglobulin-producing clone is characterized by the single type of antibody it produces, the term monoclonal antibody has been adopted. The advantages of monoclonal antibodies are numerous; they can be obtained in large supply; the preparation is homogenous with respect to antigen reactivity and remains so over time.

The principle of hybridoma/monoclonal technology is predicated on the observation that when two somatic cells are fused the resultant hybrid displays characteristics of both of the parent cell types. In the case of monoclonal antibody production, the ability to synthesize the particular antibody is derived from an immunocompetent cell (usually a spleen cell) taken from an immunized donor animal, whereas the ability to continuously divide in cell culture is contributed by the other fusion partner, a tumor cell line (often a myeloma). Early fusions were complicated by the fact that myeloma cell line also produced a monoclonal antibody; thus the hybrid often produced two types of monoclonal antibody, one of myeloma origin and the other directed by the genetic information of the immunocompetent cell. Subsequently, tumor cells lines incapable of producing their own monoclonal have been used, e.g., sp2/0-Ag14 or X63-Ag8.653, thereby simplifying the analysis of the resultant fusion products.

Another technical consideration involves the rationale for selecting the successful fusion events (hybrid cells) from the two types of parental cells. Routinely a million or more cells of each type are used in the fusion protocol, and since fusion does not occur with 100% frequency, the job of trying to recover fusion products from the high background of unfused or self-fused parents can be formidable. As mentioned hybridomas are formed by the fusion of short-lived antibody producing (spleen) cells and long-lived myeloma cells. The desired result is a long-lived cell line which produces antibody. Since the spleen cells have a finite life span in culture one can simply wait an appropriate period for all the nonfused or self-fused spleen cells to die; however one must still recover from the resultant population the long-lived antibody producing cells from the long-lived antibody non-producing cells. A popular means for selection hybrid cells is the so-called HAT-selection system. This system involves the use of the enzyme hypoxanthine-guanine-phosphoribosyl transferase (HGPRT). This enzyme functions in the purine salvage pathway in mammalian cells. These cells are also capable of synthesizing purines de novo. Under most conditions, both pathways probably operate to a certain extent. If a cell lacks HGPRT, the salvage pathway is blocked and purines must be manufactured from non-purine materials.

The chemical 8-azaguanine is an antimetabolite which is capable of masquerading as the purine guanine and replacing it in some of its normal reactions. Azaguanine is incorporated into DNA, interfering with the normal growth pattern and leading to cell death. Since azaguanine must be salvaged, any cell which lacks HGPRT activity cannot utilize azaguanine and will grow in its presence.

A selective system which operates on the same enzyme but in the opposite sense in that HGPRT positive cells are selected is described by J. W. Littlefield (Science, 145: 709 (1964)). It is called HAT and contains hypoxanthine, aminopterin and thymidine (HAT medium). Aminopterin is an antimetabolite that prevents de novo purine synthesis and methylation of deoxyuridylate to form thymidylate. Hypoxanthine can serve as a salvagable purine in the event that aminopterin blocks de novo purine biosynthesis while thymidine bypasses the necessity for the methylation of thymidylate. Thus, in the presence of aminopterin, any cell with positive HGPRT activity will proliferate while cells with negative HGPRT activity will die.

In the hybrid system used for selection in accordance with this invention, the myeloma cells are resistant to azaguanine and susceptible to aminopterin, that is, they are HGPRT negative. Thus, they will die in the presence of aminopterin. The antibody producing cells are HGPRT positive. By fusing the cells and growing them in HAT medium without azaguanine (HT medium), the successfully fused cells are selected because the myeloma cells which constitute the proliferating line can only grow where HGPRT activity is present and this activity must be supplied by the HGPRT positive cell line. The antibody producing HGPRT positive cell line are not killed in this medium. They will live for a time but will not proliferate.

Thus, by fusing the cells in a HAT medium, systems are produced in which the myeloma cells and antibody producing cells can grow long enough to produce hybrid cells but in which only the hybrid cells can survive and proliferate. After selection each hybridoma clone is then screened for the ability to produce the particular antibody of interest.

The hybridoma/monoclonal antibody technology has been tremendously successful, one indication being the dedication of an entire sub-class within United States Patent Trademark Offices classification system to monoclonal antibodies (425/548). Illustrative of the activity is the field of monoclonal antibody technology are U.S. Pat. No. 4,196,265 relating methods of producing monoclonal antibodies to viruses; U.S. Pat. No. 4,404,279 relating to methods of culturing hybridomas and increasing hybridization and U.S. Pat. No. 4,427,653 relating to a method of making monoclonal antibodies in which the antigen preparation is pre-absorbed with certain monoclonal antibodies prior to immunization. Although by no means an exhaustive list, monoclonal antibodies have been developed to the following antigens: Treponema pallidum (EPO-83302898.8), hepatitis antigens (EPO-83103858.3), anti-H-Y. (EPO-83301214.9), lens epithelial cells (83301176.0), carcinoembryonic antigen (PCT W081101469), urokinase (EPO-83100190.4), herpes (EPO-83400074.7), rat hepatocyte (82306409.2), Schistosomo mansoni (PCT W083/01837), Leishmania (PCT-WO/83/01785, transferrin receptor glycoprotein (EPO-82305658.5), rheumetoid factor (PCT WO/83/01118) cell surface antigens of human renal cancer (EPO-82107355.8) alpha interferon (PCT WO81/02899), T-cell antigen (EPO-81300047.8) human suppressor T-cells (EPO-80304348.8.

With respect to plant diseases, Hsu, H. T, et al. (ASM News 50(3): 99-101 (1984)) list 18 plant virus species to which monoclonal antibodies have been developed; included are carnation etched ring virus, potato leaf roll virus, southern bean mosaic virus, tobacco mosaic virus, tomato ringspot virus, and tulip breaking virus.

Monoclonal antibodies to fungal organisms have been developed primarily as a tool for human disease diagnosis. For example, UK Patent Applications GB2138444A and GB2138445A relate to monoclonal antibodies reactive with Candida and Aspergillus respectively.

Disclosed herein are monoclonal antibodies specifically reactive with members of the fungal family Pythiaceae and methods for their production. The antibody is particularly useful for broad range detection of Pythium infections.

BRIEF DESCRIPTION OF THE INVENTION

This invention relates to a hybridoma which produces a monoclonal antibody to an antigen from at least one strain of a member of the family Pythiaceae.

In a further embodiment the invention provides a monoclonal antibody to an antigen of at least one strain of a member of the family Pythiaceae.

In a further embodiment the invention provides a method for preparing hybridomas capable of producing monoclonal antibody to an antigen of a fungus belonging to a member of the family Pythiaceae comprising:

providing a crude extract of Pythiaceae antigen;

immunizing an animal with said extract;

recovering immunocompetent cells from said animal; fusing said immunocompetent cells with myeloma

cells to form hypbridomas; detecting those hypbridomas capable of producing monoclonal antibodies to Pythiaceae antigens by affixing the antigen to be detected to a solid support by means of glutaraldehyde cross-linking;

and indicating the presence of monoclonal antibody complexed with said affixed antigen by means of an avidin-biotin enzyme-linked immunoassay.

In a further embodiment the invention provides a method for detecting the presence of an antigen of a member of a species of the family Pythiaceae in a sample containing same comprising:

forming a binary complex between said antigen and a first antibody capable of reacting with said antigen;

forming a tertiary complex by contacting the binary complex with a second monoclonal antibody;

detecting the presence of said tertiary complex by contacting the tertiary complex with an analytically detectable immunological reagent thereby detecting the presence of the antigen.

In a final embodiment the invention provides a kit for the immunological diagnosis of Pythiaceae infection of plants comprising a carrier being compartmented to receive in close confinement therein:

an antigen extraction means;

a solid support having affixed thereto a antibody capable of forming a binary complex with Pythiaceae antigen;

a monoclonal antibody reactable with said binary complex to form a tertiary complex; and

a tertiary complex detecting means.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to methods for the production of monoclonal antibodies to Pythium aphanidermatum, the monoclonal antibodies per se, the hybridoma cell line capable of producing said antibodies and methods and kits employing the monoclonal antibodies to diagnose Pythiaceae infection in plant tissue.

Method of Extraction of Fungal Proteins

Fungi were cultured in 50 ml of PDB (Potato Dextrose Broth) medium in 250 ml flasks, (2 liters of Pythium aphanidermatum (Eds.) Fitz. were generally employed). After one week the fungal cultures were harvested from the medium, washed twice in PBS (Phosphate buffered saline; pH 7.4). Fungal cultures were transferred into a 300 ml batch chamber of a DYNO-MI11 type KDL containing 240 ml of 0.50 mm/lead-free glass beads [IMPANDEX]. Cooling jacket of the Batch chamber was pre-cooled to 8.degree. C. with cold tap water. Extract was ground at 3000 RMP for 5 minutes after which the contents of the batch chamber were transferred to 50 ml polystyrene tubes and centrifuged at 17,000 RPM (34,540 g) in a Sorvall RC-5B refrigerated centrifuge using a size SS-34 rotor. The fungal supernatant was aliquoted and frozen until use. Total protein content of samples were in the range of 0.5-2 mg/ml.

Monoclonal Antibody Production

Procedure is a modification of that developed by Kohler and Milstein (Nature 256: 495 (1975) and Hammerling (Eur. J. Immunol. 7: 743 (1977)).

INJECTIONS

Test animals 4-5 weeks old female BALB/c mice purchased from CHARLES RIVER BREEDING LABORATORIES, INC. Wilmington, Mass.

______________________________________Day 11st injection: 0.05 mg of fungal protein in 0.1 ml of PBS buffer plus 0.1 ml Freund's complete adjuvant. IP injectionDay 222nd injection: same as aboveDay 363rd injection: 0.025 mg fungal protein in 0.05 ml solution in 0.05 ml Freund's complete adjuvant. IP injectionDay 38Fusion______________________________________

Spleen isolation

Animal was sacrificed by cervical dislocation. The spleen was removed and placed in 20 ml of Dulbecco's Modified Eagle's Medium. The spleen was placed on an 80 mesh sterile screen. The spleen was then cut, perfused with DMEM (Dulbecco's Modified Eagle Medium cat no. 320-1965 Gibco Labs.) and then gently massaged with a sterile plunger from a 10 cc disposable plastic syringe. During the entire process of spleen cell extraction, the screen was continually rinsed with DMEM. Contents were pipetted into a 50 ml disposable centrifuge tube and spun down at 1200 RPM for 10 minutes (centrifugation done at room temperature). The supernatant was decanted and the cell pellet washed with 10 mls of red blood cell lysing solution (0.83% NH4Cl; 0.01 M KHC03; 0.1 mM EDTA) for 90 seconds at room temperature. The lysing reaction was stopped by diluting with 40 mls of DMEM. The sample was left to stand for 3 minutes, and the supernatant pipetted to 50 ml centrifuge tubes. After centrifugation, the pellet was washed with 50 ml of DMEM and recentrifuged. The final pellet was resuspended with 5 ml of DMEM. A small sample of the spleen cells was retained for counting and to check for cell viability. Optimal concentration of spleen cells is 10 to the 7 cells per ml.

Myeloma cells (SP2-0-Ag 14) obtained from American Type Culture Collection) were transferred (concentration 1.times.10.sup.6 cells per ml) from culture into a 50 ml Falcon tube. The myeloma cells for fusion were centrifuged (1200 RPM for 10 minutes at room temperature). After centrifugation, the supernatant was discarded into a clean glass beaker, the cells were washed with DMEM, and recentrifuged. The spleen cells were added to the tube containing the washed myeloma pellet. The myeloma and spleen cells were gently resuspended with the aid of a 10 ml pipette and automatic pipetter and centrifuged for 10 minutes at 1200 RPM at room temperature. Following centrifugation, the supernatant was decanted.

Fusion

The fusion medium, 50% PEG (polyethylene glycol) 1500 (M.A. Bioproducts Cat. #17-7802) prewarmed to 47.degree. C., was suspended in DMEM. One ml of fusion medium was added dropwise to the tube containing the resuspended myeloma and spleen cells - time thirty seconds. The final 7 minutes of the fusion reaction was to allow the gradual dilution of the PEG with DMEM. At the end of the dilution, the final volume in the tube reached 50 mls. During the entire fusion period, the tube was gently tapped to insure proper mixing of the material. The tube was then centrifuged (1200 RPM for 10 minutes at room temperature) and the supernatant removed. Prewarmed HAT medium (described below) (33 ml) was added to the tube, and the cellular contents were suspended using a 10 ml pipette. The final concentration of spleen cells was 1.4.times.10.sup.6 cells.

Cells were then added to the 60 central wells of a 96 well microtiter plate (Limbro multiwell). To each well was added 150 .mu.l of fused Myeloma/Spleen material. Outer wells of the microtiter plate were then filled with HAT medium. Microtiter plates were placed in a water jacketed 7% CO.sub.2 incubator, temperature 37 C.

Cells were refed with HAT medium every 4 days. Visible hybridoma growth began to appear after 7 to 10 days.

TABLE II______________________________________HAT Medium CompositionDULBECCO'S MODIFIED EAGLE MEDIUM 766 mlcat #320-1965 GIBCO LABSL Glutamine (200 mM) 100 .times. concentration 10 mlcat #320-5030 GIBCO LABSPencillin/Streptomycin solution: 10 ml10,000 u/ml 10 mg/mlcat #P0781 SIGMAAminopterin (50 .times.) 4 mlcat #A-5159 SIGMAHypoxanthine/Thymidine solution: 10 mlThymidinecat #T-9250 SIGMA 38.8 mgHypoxanthinecat #H-9377 SIGMA 136.1 mgadd 100 ml sterile water and pH to 8.5 withsterile 1 N NaOHFetal Bovine Serum 200 mlcat #12-10378 HAZLETON DUTCHLAND, INC.______________________________________

Screening for Hybridomas

Those hybridomas producing antibodies to fungal pathogens were identified by using prepared Pythium aphanidermatum (Eds.) Fitz. fungal material (protein concentration 15 .mu.g/ml in PBS buffer) in an avidin/biotin amplified glutaraldehyde ELISA format.

Screening Protocol

This procedure relates to an enhancement procedure for screening hybridomas secreting antibodies to fungal pathogens.

AVIDIN/BIOTIN GLUTARALDEHYDE

ELISA SCREENING

ELISA - GLUTARALDEHYDE Procedure

1. 200 .mu.l of glutaraldehyde buffer was placed into each well (Immulon I plates), incubated for 3 hours at 55 C., cooled to room temperature and the plates washed 3 times with deionized (DI) water.

2. 200 .mu.l of antigen diluted in 0.15M PBS, pH 7.2, was dispensed into each well. One row was left empty for use as the glutaraldehyde control. The mixture was incubated for 24 hours at 4 C, the remaining suspension discarded and washed 3X with PBS.

3. 200 .mu.l of (mono)ethanolamine solution was dispersed into each well, incubated for 20 hours at 4C, the remaining solution discarded and plate washed 3X with PBS.

4. 200 .mu.l of appropriate serum sample diluted with 0.15M PBS, pH 7.2 was placed into each well, incubated for 2 hours at 33.degree. C. with humidity. The remaining solution was discarded and the plate washed 3X with PBS.

5. The supernatants were aspirated and washed 2 times with 200 .mu.l PBS.

6. Biotinylated anti-mouse IgG or IgM; peroxidase conjugated avidin reagent (VECTOR LABORATORIES mouse anti IgG or IgM; ABC reagent)

10 ml PBS+100 .mu.l normal horse serum+1 drop biotinylated anti-mouse IgG

10 ml PBS (0.1% tween) add 2 drops ABC reagent A immediately add 2 drops ABC reagent B, mix and let stand for 30 minutes before using.

7. 50 .mu.l/well biotin/anti-mouse solution was added and incubated for 15 minutes at room temperature.

8. The mixture was aspirated and washed 2 times with 200 .mu.l PBS.

9. ABC reagent (see above) was added at 50 .mu.l/well incubated 15 minutes at room temperature, then aspirated and washed 5 times with 200 .mu.l PBS/well.

10. The following substrate solution was added at 200 .mu.l/well.

Citrate Phosphate Buffer 7.1 g Na.sub.2 HPO.sub.4 (500 ml) 9.6 g citric acid (500 ml)

adjust pH of first solution to 6.0 by adding citric acid

50 ml buffer

20 mg Phenylenediamine-HCL 1,2 benzenediamine (OPD)

Sigma P 3888

167 .mu.l 3% H.sub.2 O.sub.2

The mixture was incubated at room temperature for 10 minutes and absorbance read at 405 nm.

Required solutions

1. Glutaraldehyde buffer: 0.1% glutaraldehyde in 0.1M carbonate buffer. The carbonate buffer, pH 9.0, consists of 1.57g Na2CO.sub.3 and 2.93g NaHCO.sub.3 per liter of DI water.

2. PBS-tween: 8.0 NaCl, 0.2 g KH.sub.2 PO.sub.4, 2.9 g, 1.15 g Na.sub.2 HPO.sub.4 anhydrous, 0.2 g KCl, per liter of DI water, pH 7.4.

3. (Mono)ethanolamine solution: 1 mg/ml solution (lg/liter of DI water).

Subcloning Procedure

Those wells giving positive responses to the ELISA tests undergo a limiting dilution so that pure strains of hybridoma cells might be grown. The limiting dilution method involved culturing serially diluted suspensions of hybridomas. Each dilution series was set up in 6-12 wells of a 96 well culture plate. These wells were then retested for specific antibody activity to fungal proteins. Positive wells were then transfered to 20 ml culture flasks for mass culturing.

Characterization of Clone # PA5IIIF11 and # PA6VIF9-E8-C6

Clone # PA5IIIF11 secretes antibodies of the IgM class against Pythium aphanidermatum (Eds.) Fitz

Clone # PA6VIF9-E8-C6 secretes antibodies of the IgG, class against Pythium aphanidermatum (Eds.) Fitz

Avidin/Biotin with Glutaraldehyde enhancement ELISA screening against four plant pathogens. Incubation of enzyme substrate reaction was performed at room temperature.

TABLE III______________________________________Absorbance (405 nm) 10 minute incubation with enzyme substrate[Peroxidase conjugate]______________________________________ F11/F9Pythium aphanidermatum 1.15/ pathogen concentration(Eds.) Fitz 0.78 10 .mu.g/mlRhizoctonia solani 0.09/ pathogen concentrationKuhn. 0.16 10 .mu.g/mlRhizoctonia cerealis 0.16/ pathogen concentrationVan der Hoaven 0.11 10 .mu.g/mlSclerotinia homoeocarpa 0.22/ pathogen concentrationBennett 0.06 10 .mu.g/mlno antigen control 0.00/Phosphate buffered 0.05salineculture supernatant 0.01/control; Dulbecco's 0.01Modified EaglesMedium with 15%Fetal Calf Serum______________________________________ELISA crossreactivity tests with diseased turf Absorbancealkaline phosphatase conjugate F11______________________________________Pennlawn infected with Pythium aphanidermatum 0.68Pennlawn uninfected 0.02Fylking infected with Rhizoctonia cerealis 0.01Fylking uninfected 0.03Penncross infected with Sclerotinia homoeocarpa 0.05Penncross uninfected 0.02No antigen (Phosphate Buffered Saline) 0.00Uninfected grass:Penncross 0.05Agrostis tenuis SibthPennlawn 0.02Festuca rubravar. commutata Gaud.Fylking 0.04Kentucky BluegrassPoa pratensis L.______________________________________

To further test the reactivity of two of the clones isolated by the above procedure, F11, an IgM secreting type, and F-9, and IgG secreting-type were screened against a variety of fungal strains employing the avidin/biotin system described above.

TABLE IV______________________________________TESTS WITH F11 SUPERNATANTS (IgM)Culture samples Source Absorbance Reaction______________________________________P. aphanidermatumPA-1 Larsen from .55 + Schmitthener- Wooster OhioPA-2 Cole - .52 + Penn StatePA-3 Cole - .84 + Penn StatePA-4 Wilkinson- .45 + IllinoisPA-5 ATCC .49 + #36431PA-6 ATCC .57 + #26081PA-9 Schmitthenner .58 + Wooster, OhioPA-10 P. Sanders .81 + OhioPA-11 P. Sanders .61 + OhioPA-13 P. Sanders .55 + OhioP. paroecandrum Hagedorn .67 + Madison, Wis.P. salpingophorum Hagedorn .66 + Madison, Wis.P. sylvaticum Hagedorn .71 + Madison, Wis.P. ultimumPu-1 Hagedorn .85 + Madison, Wis.Pu-2 Hagedorn .78 + Madison, Wis.Pu-3 Hagedorn .72 + Madison, Wis.R. cerealis .09 -Brown PatchR. solani Lucas .06 -RS-1 North CarolinaRS-2 Cole .03 - Penn StateRS-3 Cole .04 - Penn StateRS-5 Lucas .02 - North CarolinaRS-7 ONeil .04 - Beltsville, Md.Dollar SpotSclerotinia homoeocarpaSH-1 Cole .05 - Penn State______________________________________ TABLE V______________________________________TESTS WITH F9 SUPERNATANTS (IgG)Culture samples Source Absorbance Reaction______________________________________P. aphanidermatumPA-1 Larsen from .32 + Schmitthener- Wooster OhioPA-2 Cole- .30 + Penn StatePA-3 Cole- .31 + Penn StatePA-4 Wilkinson- .14 + IllinoisPA-5 ATCC .26 + #36431PA-6 ATCC .41 + #26081PA-9 Schmitthenner .27 + Wooster, OhioPA-10 P. Sanders .21 + OhioPA-11 P. Sanders .22 +PA-13 P. Sanders .14 + OhioP. paroecandrum Hagedorn .12 +/- Madison, Wis.P. salipingophorum Hagedorn .03 + Madison, Wis.P. sylvaticum Hagedorn .71 + Madison, Wis.P. ultimumPu-1 Hagedorn .36 + Madison, Wis.Pu-2 Hagedorn .02 - Madison, Wis.Pu-3 Hagedorn .06 - Madison, Wis.Yellow Patch .09 -R. cerealisBrown PatchR. solaniRS-1 Lucas .02 - North CarolinaRS-2 Cole .00 - Penn StateRS-3 Cole .06 - Penn StateRS-5 Lucas .01 - North CarolinaRS-7 ONeil .01 - Beltsville, MdDollar SpotSclerotinia homoeocarpaSH-1 Cole .04 - Penn State______________________________________

A further set of experiments were conducted to demonstrate reactivity of F9 and F11 supernatants with other members of the Pythiaceae. The experiments were conducted with a second set of supernatants derived from the F9 and F11 clones described above; thus, although the absolute absorbance values are not comparable with those shown above, the pattern of reactivity is identical. These experiments demonstrate that the monoclonal antibodies produced by the F9 and F11 clones also react with members of the genus Phytopthora.

TABLE VI______________________________________ F9 F11Culture Sample (IgG) (IgM) Reaction______________________________________Pythium aphanidermatum (Edson) FitzPA 7 .35 .35 +PA 14 .26 .36 +PA 15 .64 .37 +PA 16 .39 .30 +PA 17 .27 .30 +PA 1 .12 .32 +Pythium irregulare (Buisman) .48 .33 +PI 1Pythium myriotylum (Drechsler)PMY 1 .44 .28 +PMY 2 .48 .36 +Pythium vexans (deBary) .17 .31 +PV 1Pythium coloratum (Vaartaja) .16 .29 +PC 1Phytopthora parasiticavar nicotinae (Tucker)PPN 0 .19 .34 +PPN 1 .15 .27 +Phytopthora parasitica (Dastur.) .63 .32 +P. parasit.Rhizoctonia solani .03 .00 -Rhizoctonia cerealis .01 .00 -Sclerotinia homoeocarpa .01 .00 -Phosphate Buffered Saline .00 .00 -(Control)______________________________________

Deposit of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of the following hybridomas were made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland on Mar. 14, 1985 and July 18, 1985 the accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said culture will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. .sctn.1.14 and 35 U.S.C. .sctn.122. All restriction on availability of said culture to the public will be irrevocably removed upon the granting of a patent based upon the application and said culture will remain permanently available for a term of at least five years after the most recent request for the furnishing of a sample and in any case for a period of at least 30 years after the date of the deposit. Should the culture become nonviable or be inadvertently destroyed, it will be replaced with a viable culture(s) of the same taxonomic description.

______________________________________Hybridoma ATCC No.______________________________________Balbc/SP2 PA5III F11 8750Balbc/SP2 PA6VI F9-E8-C6 8878______________________________________

Detection of Fungal Pathogens and Kits Therefor

This invention contemplates the use of the monoclonal antibodies described above in a system for detection of Pythiaceae infection. Accordingly, a sample of plant material suspected of harboring the organism is subjected to an extraction procedure whereby the plant material is physically disrupted such as by grinding and the resultant crude extract is diluted into water or buffer. A sample of the crude extract is contacted with a first antibody specifically reactive with an antigenic determinant of the organism to be detected. Preferably the antibody is immobilized on a solid support such as the walls of a microtiter plate. The antibody may be monoclonal antibody or a component of polyclonal sera. After removing the unreacted material by washing, the resulting binary complex (antigen-antibody complex) is contacted with monoclonal antibody specifically reactive to the antigen to be detected. Of course if a monoclonal is employed as the first antibody the second monoclonal should be reactive with a different antigenic determinant than the first monoclonal, unless it can be shown that the determinant is present in multiple copies in the antigen. By contacting the immobilized binary complex with the second monoclonal antibody, a tertiary complex is formed. After washing to remove any of second antibody which did not bind to the binary complex, the tertiary complex may be detected by a variety of analytical techniques. The second monoclonal could be labelled directly and the tertiary complex indicated. Alternatively, the ELISA system described above may be employed whereby the tertiary complex is reacted with an biotin-labelled anti-immunoglobulin and that reaction product is subsequently contacted with an avidin-enzyme reagent. Once reacted, the substrate of the enzyme is added and the enzyme reaction product detected, thus indicating the presence of the organism or antigen therefrom.

To facilitate the detection the various reactants are provided in the form of a kit.

Claims

1. A hybridoma which produces a monoclonal antibody which is capable of forming a complex with antigens from at least 20 strains of the family Pythiaceae.

2. The hybridoma of claim 1 wherein said monoclonal antibody is selected from the group consisting of the IgG and IgM classes.

3. The hybridoma according to claim 2 wherein said monoclonal is of the IgM class.

4. The hybridoma according to claim 3 having the identifying characteristics of ATCC 8750.

5. The hybridoma according to claim 2 wherein said monoclonal is of the IgG class.

6. The hybridoma according to claim 5 having the identifying characteristics of ATCC 8878.

7. A monoclonal antibody which is capable of forming a complex with antigens from at least 20 strains of the family Phthiacea.

8. The monoclonal antibody according to claim 7 wherein said antibody is selected from the group consisting of the IgG and IgM classes.

9. The monoclonal antibody according to claim 8 wherein said antibody is of the IgM class.

10. The monoclonal antibody according to claim 8 wherein said antibody is of the IgG class.

11. The monoclonal antibody produced by culturing the hybridoma of claim 1 under monoclonal antibody producing conditions.

12. The monoclonal antibody produced by culturing the hybridoma of claim 4 under monoclonal antibody producing conditions.

13. The monoclonal antibody produced by culturing the hybridoma of claim 6 under monoclonal antibody producing conditions.

14. The monoclonal antibody according to claim 12 or 13 wherein said monoclonal is labelled with an analytically detectable reagent.

15. The monoclonal antibody according to claim 14 wherein said reagent is selected from the group consisting of a fluorescent dye, radio label and an enzyme.

16. The monoclonal antibody according to claim 12 or 13 wherein said monoclonal antibody is immobilized into a solid support.

17. The hybridoma according to claim 1 wherein the strains are selected from the group consisting of strains of the genus Pythium and the genus Phytophthora.

18. The monoclonal antibody according to claim 7 wherein the strains are selected from the group consisting of strains of the genus Pythium and the genus Phytophthora.